30 closest matches · ranked by relevance
Thrombocythemia, Hemorrhagic
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time — 66.4; 66.9; 0.5; -1.1 percentage of ejection fraction
Atherosclerosis
Primary: Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From…
Essential Thrombocythemia (ET)
Primary: Percentage of Subjects Who Responded in Platelet Count — 67.9 percentage of subjects
High Risk Polycythemia Vera · High Risk Essential Thrombocythemia
Primary: Number of Participants With Complete Remission (CR) — 17; 19; 12; 13 Participants
Essential Thrombocythemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 73 Participants
Essential Thrombocythemia (ET)
Primary: Change From Baseline in Platelet Count at Final Assessment — 1021.6; -346.2 10^9 platelets per liter (10^9/L)
Myeloproliferative Diseases
Primary: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response — 2; 12; 2; 1 Participants
Essential Thrombocythemia (ET)
Primary: Number of Participants Who Had One or More Adverse Events — 776 Participants
Essential Thrombocythaemia
Primary: Maximum Plasma Concentration (Cmax) of Agrylin — 2.66; 3.63 ng/ml — p=0.092
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Acute Myeloid Leukemia · Essential Thrombocythemia
Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Essential Thrombocythemia
Primary: Percentage of Subjects With Continuation of Anagrelide Hydrochloride at 6 Months: Withdrawal of Previous Cytoreductive Therapy Before Anagrelide Hydrochloride Initiation…
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Myeloproliferative Disorders
Primary: Number of Patients With Complete Response (CR) or Partial Response (PR) — 3; 3; 14; 23 Participants
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants
Polycythemia Vera · Essential Thrombocythemia · Primary Myelofibrosis
Primary: Influence of Pre- and Post- Incentives on Participation Rates. — 4; 6; 15; 69 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants
Essential Thrombocythemia (ET)
Primary: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months — 12; 14 participants
Anemia, Aplastic · Anemia, Hypoplastic · Thrombocytopenia
Primary: The Portion of Drug Responders as Defined by Hematologic Improvements — 17 Participants
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Polycythemia Vera
Primary: Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study — 3; 3; 3; 3 Participants
Polycythemia Vera
Primary: Number of Participants With Adverse Events - All Grades — 143; 26 Participants
Primary Myelofibrosis (PMF) · Post-Polycythaemia Vera · Essential Thrombocythaemia Myelofibrosis
Primary: Pharmacokinetic Parameters Following Single Dosing: AUC0-12 — 69.2; 295; 278; 1860 ug*h/L